An examination of a novel multipanel of CSF biomarkers in the Alzheimer's disease clinical and pathological continuum
Year: 2020
Type: article
Study design: Observational Study
Abstract: Introduction This study examines the utility of a multipanel of cerebrospinal fluid (CSF) biomarkers complementing Alzheimer's disease (AD) biomarkers in a clinical research sample. We compared biomarkers across groups defined by clinical diagnosis and pTau181/Aβ42 status (+/−) and explored their value in predicting cognition. Methods CSF biomarkers amyloid beta (Aβ)42, pTau181, tTau, Aβ40, neurogranin, neurofilament light (NfL), α‐synuclein, glial fibrillary acidic protein (GFAP), chitinase‐3‐like protein 1 (YKL‐40), soluble triggering receptor expressed on myeloid cells 2 (sTREM2), S100 calcium binding protein B (S100B), and interleukin 6 (IL6), were measured with the NeuroToolKit (NTK) for 720 adults ages 40 to 93 years (mean age = 63.9 years, standard deviation [SD] = 9.0; 50 with dementia; 54 with mild cognitive impairment [MCI], 616 unimpaired). Results Neurodegeneration and glial activation biomarkers were elevated in pTau181/Aβ42+ MCI/dementia participants relative to all pTau181/Aβ42‐ participants. Neurodegeneration biomarkers increased with clinical severity among pTau181/Aβ42+ participants and predicted worse cognitive performance. Glial activation biomarkers were unrelated to cognitive performance. Discussion The NTK contains promising markers that improve the pathophysiological characterization of AD. Neurodegeneration biomarkers beyond tTau improved statistical prediction of cognition and disease stages.
Source: Alzheimer s & Dementia
DOI: 10.1002/alz.12204
Institutions: University of Wisconsin–Madison, Novartis (Switzerland), Roche Diagnostics International AG (Switzerland), University of Gothenburg, William S. Middleton Memorial Veterans Hospital, Sahlgrenska University Hospital, UK Dementia Research Institute, UCL Queen Square Institute of Neurology, University College London
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,000
Awards: G1253720191, G1551449788, G2108271864, Alzheimer's Disease Connectome Project, G2360966051, G2385484910, The Alzheimer biomarker toolbox – use in pathogenic studies, diagnostics and theragnostics, G2841269746, G3027168043, G308275008, G313301595, G3404729342, G3763846736, G4075158157, G4181470480, Wisconsin Registry for Alzheimer's Prevention, G4656487552, White matter degeneration: biomarkers in preclinical Alzheimer's Disease, G565506342, G56684467, G6142763750, G6168044258, Institutional Clinical and Translational Science Award, Wisconsin Alzheimer's Disease Research Center, Longitudinal Investigation of Cardiorespiratory Fitness and AD Biomarkers in an At-Risk Cohort, SV2A PET imaging in Alzheimer's Disease, G7143958211, G791739130, University of Wisconsin Institute for Clinical and Translational Research, The Longitudinal Course of Imaging Biomarkers in People At Risk for Alzheimer’s Disease, Wisconsin Registry for Alzheimer's Prevention, Wisconsin Alzheimer's Disease Research Center, G958583170, G96521508
OpenAlex ID: W3112012188